Wolverine Trading’s Travere Therapeutics TVTX Stock Holding History

Wolverine Trading’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,800	Closed	-$187K	–	5872
2024 Q4	$187K	Buy	+10,800	New	+$191K	﹤0.01%	4565
2022 Q1	–	Sell	-8,000	Closed	-$242K	–	6468
2021 Q4	$242K	Buy	+8,000	New	+$225K	﹤0.01%	4438
2021 Q1	–	Sell	-7,600	Closed	-$210K	–	6416
2020 Q4	$210K	Buy	+7,600	New	+$177K	﹤0.01%	4170
2019 Q4	–	Sell	-12,300	Closed	-$146K	–	5227
2019 Q3	$146K	Sell	12,300 -7,700	-39%	-$127K	﹤0.01%	3730
2019 Q2	$402K	Sell	20,000 -4,400	-18%	-$86.9K	﹤0.01%	2946
2019 Q1	$552K	Buy	24,400 +14,400	+144%	+$318K	﹤0.01%	2664
2018 Q4	$223K	Buy	+10,000	New	+$249K	﹤0.01%	3582
2017 Q1	–	Sell	-11,600	Closed	-$220K	–	5014
2016 Q4	$220K	Sell	11,600 -17,400	-60%	-$356K	﹤0.01%	3644
2016 Q3	$635K	Buy	29,000 +3,900	+16%	+$74.2K	﹤0.01%	2339
2016 Q2	$451K	Buy	+25,100	New	+$406K	﹤0.01%	2323

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Wolverine Trading's TVTX Position: Q1 2019 in Review

Wolverine Trading sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 10,632 shares — an estimated $235K sold.

Wolverine Trading first reported a position in TVTX in Q2 2016 and held it in 2 quarters. The position peaked at $394K in Q2 2016. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

Wolverine Trading reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
Wolverine Trading sold 10,632 Travere Therapeutics shares in Q1 2019, an estimated $235K.
Wolverine Trading first reported a position in Travere Therapeutics in Q2 2016 and held it in 2 quarters.
Wolverine Trading's Travere Therapeutics position peaked at $394K in Q2 2016.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Wolverine Trading's 13F filing for Q1 2019, filed 15 May 2019.